Neurologic Aspects of Systemic Disease, Part II

Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)
 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 9. Januar 2014
  • |
  • 736 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-7020-4433-5 (ISBN)
 

Systemic disease involves several parts of the body or the complete system. Neurologic Aspects of Systemic Disease, a two-part volume in the Handbook of Clinical Neurology series, focuses on the specific neurologic aspects of systemic disease.

Part 2 includes coverage of gastrointestinal and hepatobiliary, endocrinologic, and metabolic diseases, as well as nutritional, environmental, and hematologic disorders. Each chapter provides a complete introduction to the neurologic aspect and provides the best known diagnostic and treatment practices. The collection is a valuable and trusted resource for clinical neurologists, research neurologists, neuroscientists, and general medical professionals: a first stop for a focused review of the state of the art for understanding the neurologic impact of each covered disease.


  • A comprehensive introduction and overview of the neurologic aspects of systemic disease
  • Part 2 covers of gastrointestinal/hepatobiliary, endocrinologic, and metabolic diseases and nutritional, environmental, and hematologic disorders
  • Each chapter focuses on the neurologic aspects related to a specific disease presentation
0072-9752
  • Englisch
  • Amsterdam
  • |
  • Niederlande
Elsevier Science
  • 33,02 MB
978-0-7020-4433-5 (9780702044335)
0702044334 (0702044334)
weitere Ausgaben werden ermittelt
  • Front Cover
  • Neurologic Aspects of Systemic Disease
  • Copright
  • Handbook of Clinical Neurology 3rd Series
  • Foreword
  • Preface
  • Contributors
  • Contents of Part II
  • Contents of Part I
  • Contents of Part III
  • Section 5: Neurologic Aspects of Gastrointestinal/hepatobiliary diseases
  • Chapter 39: The Neurologic Complications of Bariatric Surgery
  • Obesity: an Overview
  • Bariatric Surgery
  • Neurologic Complications of Bariatric surgery
  • Thiamine Deficiency (vitamin B1)
  • Copper Deficiency Myelopathy
  • Other Nutritional and Metabolic Disorders
  • Miscellaneous Disorders
  • Conclusions
  • References
  • Chapter 40: Neurologic Manifestations of Inflammatory Bowel Diseases
  • Introduction
  • Neurologic Manifestations in Inflammatory Bowel Disease
  • Prevalence
  • Pathophysiology
  • Peripheral Nervous System
  • Cranial Neuropathies
  • Cerebrovascular Complications
  • Pathophysiology
  • Arterial Ischemic Stroke
  • Stroke and anti-TNF-a Therapy
  • Vasculitis
  • Cerebral Venous Thrombosis
  • Demyelinating Disease
  • Other Central Nervous System Complications
  • Psychiatric Syndromes
  • Medication-induced Neurolgic Complications
  • Steroids
  • Metronidazole
  • Ciclosporin
  • Anti-Tnf-a Agents (infliximab, Adalimumab, Certolizumab)
  • Anti-a4 Integrin (natalizumab)
  • References
  • Chapter 41: Gluten-related Neurologic Dysfunction
  • Historical Perspective
  • Epidemiology of Neurologic Manifestations
  • The Diagnosis of gluten-related diseases
  • The Spectrum of gluten-related Neurologic Manifestations
  • Gluten Ataxia
  • Gluten Neuropathy
  • Gluten Encephalopathy (headache and White matter Abnormalities)
  • Myoclonic Ataxia
  • Epilepsy
  • Myopathy
  • Myelopathy
  • Stiff Man Syndrome
  • Pathogenesis
  • Conclusions
  • References
  • Chapter 42: Neurologic Manifestations of Malabsorption Syndromes
  • Introduction
  • Absorption and Malabsorption
  • Absorption of Nutrients
  • Malabsorption
  • Neurologic Dysfunction in Malabsorption Syndromes
  • Vitamin E Deficiency
  • Familial Hypocholesterolemia
  • Celiac Disease
  • Tropical Sprue
  • Wernicke's Encephalopathy
  • Pellagra
  • Copper Deficiency Myelopathy
  • Whipples Disease
  • Conclusion
  • References
  • Chapter 43: Commonly Used Gastrointestinal Drugs
  • Introduction
  • Antiemetics
  • Phenothiazines
  • Metoclopramide
  • Domperidone
  • Setrons (5-hydroxytryptamine 3 (5-HT3) Receptor Antagonists, Serotonin 3 Receptor antagonist)
  • Neurokinin Receptor Antagonists
  • Drugs Affecting Gastrointestinal Motility
  • Promotility Drugs
  • Antimotility and Antidiarrheal Agents
  • Laxatives
  • Drugs for acid-related Disorders
  • Central Hyperthermia Syndromes and Gastrointestinal Drugs
  • Conclusion
  • Acknowledgement
  • References
  • Chapter 44: Neurologic Manifestations of Acute Liver Failure
  • Introduction
  • Historical Perspective
  • Clinical Presentation
  • Laboratory Tests and Imaging studies
  • Referral to Transplant Center
  • Medical Management of Acute Liver Failure
  • Management of Cerebral Edema
  • Outcome
  • Artificial Livers
  • References
  • Chapter 45: Portosystemic Encephalopathy
  • History
  • Clinical Findings
  • Differential Diagnosis
  • Diagnosis of Minimal Hepatic Encephalopathy
  • Natural History
  • Laboratory Investigations
  • Neuroimaging Investigations
  • Pathology/pathophysiology
  • Management
  • Conclusions
  • References
  • Chapter 46: Neurotoxicity of Commonly Used Hepatic Drugs
  • Introduction
  • Calcineurin Inhibitors
  • Mechanism of Action
  • Neurotoxicity
  • Mechanism of Neurotoxicity
  • Specific Complications
  • Treatment of Complications
  • Other Medications Used for Immunosuppresion after Orthotopic Liver Transplantation
  • Sirolimus
  • Mycophenolate Mofetil (CellCept)
  • Interferons, Ribavirin and Nucleoside and Nucleotide Analogs Used in the Treatment of Hepatitis B and C Virus
  • Interferons
  • Mechanism of Action
  • Neurotoxicity
  • Ribavirin
  • Mechanism of Action
  • Neurotoxicity
  • Lamivudine
  • Mechanism of Action
  • Neurotoxicity
  • Adefovir Dipivoxil (Hepsera)
  • Mechanism of Action
  • Neurotoxicity
  • Entecavir (Baraclude)
  • Mechanism of Action
  • Neurotoxicity
  • Telbivudine (Tyzeka®)
  • Mechanism of Action
  • Neurotoxicity
  • Conclusions
  • References
  • Section 6: Neurologic Aspects of Endocrinologic Diseases
  • Chapter 47: Neurology of the Pituitary
  • Background
  • Pituitary Adenomas: Epidemiology and Pathogenesis
  • Neurologic Manifestations of Pituitary Lesions
  • Hypopituitarism
  • Secondary Adrenal Insufficiency
  • Secondary Hypothyroidism
  • Secondary Hypogonadism
  • Growth Hormone Deficiency
  • Prolactin Deficiency
  • Central Diabetes Insipidus
  • Evaluation of the Hypothalamic-pituitary Axis
  • Hormonal Hyperfunction
  • Hyperprolactinemia
  • Prolactinomas
  • Growth Hormone Excess
  • Acromegaly
  • Excess ACTH
  • Cushings Disease
  • Thyroid-stimulating Hormone Excess
  • TSH-producing Adenomas
  • Gonadotropin-producing Adenomas
  • Nonfunctional Adenomas
  • Imaging
  • Management of Pituitary Tumors
  • Observation
  • Surgical Management
  • Postoperative Complications
  • Medical Management
  • Prolactinomas
  • Acromegaly
  • Cushings Disease
  • Radiotherapy
  • Future Directions
  • References
  • Chapter 48: Thyroid Disease and the Nervous System
  • Introduction
  • Neurologic Complications of Hypothyroidism
  • The Neurology of Congenital Hypothyroidism
  • Etiology of Permanent Congenital Hypothyroidism
  • Clinical and Radiologic Features
  • Pathogenesis
  • Treatment and Prognosis
  • Encephalopathy, Coma, and Seizures
  • Myxedema Coma
  • Clinical Features
  • Laboratory Investigations
  • Management of Myxedema Coma
  • Seizures
  • Mental Changes
  • Peripheral Neuropathy
  • Entrapment Neuropathy
  • Diffuse Peripheral Neuropathy
  • Disorders of Sleep
  • Cerebellar Ataxia
  • Cranial Nerve Disorders
  • Hypothyroid Myopathy
  • Clinical Features
  • Investigations
  • Pathology
  • Pathophysiology
  • Treatment and Prognosis
  • Miscellaneous Neurologic Conditions and Hypothyroidism
  • Myasthenia Gravis
  • Giant Cell Arteritis and Polymyalgia rheumatica
  • Hypothyroidism Related to Anticonvulsant therapy
  • Neuroleptic Malignant Syndrome
  • Neurologic Complications of Hyperthyroidism and Graves' disease
  • Hyperthyroid Myopathy
  • Clinical Features
  • Investigations
  • Physiologic and Biochemical Changes In skeletal Muscle
  • Treatment and Prognosis
  • Myopathy With Raised Creatine Kinase on Commencement of Treatment for Hyperthyroidism
  • Inflammatory Myopathy in Hyperthyroidism
  • Peripheral Neuropathy
  • Corticospinal Tract Disorders
  • Movement Disorders
  • Tremor
  • Chorea and Other Movement Disorders
  • Thyroid-associated Ophthalmopathy (Graves Ophthalmopathy)
  • Clinical Features
  • Diagnostic Tools
  • Pathogenesis
  • Treatment
  • Prognosis
  • Thyrotoxic Hypokalemic Periodic Paralysis
  • Clinical Features
  • Neurologic Features
  • Non-neurologic Features
  • Diagnosis
  • Pathophysiology
  • Management
  • Emergency Treatment
  • Prevention of Further Attacks Pending Resolution of Hyperthyroidism
  • Definitive Treatment of the Underlying hyperthyroidism
  • Thyroid Storm
  • Seizures
  • Mental and Psychiatric Disorders
  • Miscellaneous Conditions Associated With hyperthyroidism
  • Headache
  • Cerebral Venous Sinus Thrombosis
  • Stroke
  • Hashimotos Encephalopathy
  • Clinical Features
  • Pathophysiology
  • Neuropathology
  • Diagnosis
  • Differential Diagnosis
  • Antithyroid Antibodies
  • Other Diagnostic Tests
  • Treatment
  • Miscellaneous Neurologic Disorders and Thyroid Disease
  • Myasthenia Gravis
  • Multiple Sclerosis and Thyroid Disease
  • Endocrine Dysfunction in long-term Survivors of Primary Brain Tumors
  • Recurrent Laryngeal Nerve Palsy
  • References
  • Chapter 49: Neurologic Disorders of Mineral Metabolism and parathyroid disease
  • Calcium, Phosphorus, and Magnesium Homeostasis
  • Disorders Associated With Hypercalcemia
  • Primary Hyperparathyroidism
  • Pathophysiology
  • Overview of the Clinical and Biochemical Features of Primary Hyperparathyroidism
  • Neurologic and Muscular Manifestations of Symptomatic Primary Hyperparathyroidism
  • Neurologic and Muscular Manifestations of asymptomatic Primary Hyperparathyroidism
  • Neurologic Manifestations of Hypophosphatemia
  • Other Etiologies of Hypophosphatemia
  • Neurologic Manifestations of Hypomagnesemia
  • Other Etiologies of Hypomagnesemia
  • Management of Hypercalcemia, Including Primary Hyperparathyroidism
  • Disorders Associated With Hypocalcemia
  • Pathophysiology
  • Secondary and Tertiary Hyperparathyroidism
  • Clinical Features of Hypocalcemia
  • Pseudopseudohypoparathyroidism
  • Management of Hypocalcemia
  • Conclusion
  • References
  • Chapter 50: Neurologic Complications of Disorders of the Adrenal Glands
  • Introduction
  • Historical Aspects
  • Function of the Adrenal Glands
  • Cushing Syndrome
  • Historical Aspects
  • Etiology
  • Clinical Manifestations
  • Diagnosing Cushing Syndrome
  • Diagnosing the Cause of Cushing Syndrome
  • Treatment
  • Adrenal Insufficiency
  • Historical Aspects
  • Etiology and Pathogenesis
  • Disorders Causing Destructive Lesions
  • Pathophysiology of Autoimmune Addison Disease
  • Disorders Caused By Developmental Defects
  • Disorders Causing Impaired Steroidogenesis
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Adrenoleukodystrophy and Adrenomyeloneuropathy
  • Historical Aspects
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Hyperaldosteronism
  • Historical Aspects
  • Etiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Disorders of the Adrenal medulla
  • Historical Aspects
  • Etiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Acknowledgements
  • References
  • Chapter 51: Diabetic Neuropathy
  • History and Epidemiology
  • Classification and Clinical findings
  • Sensory or Sensorimotor Polyneuropathy
  • Selective Small Fiber Polyneuropathy
  • Autonomic Neuropathy
  • Focal and Multifocal Neuropathies
  • Cranial Neuropathy
  • Limb Mononeuropathy (compression and Entrapment Neuropathies)
  • Trunk Mononeuropathy
  • Asymmetric Lower Limb Motor Neuropathy (amyotrophy)
  • Laboratory Investigations
  • Risk Factors
  • Pathophysiology
  • Oxidative Stress
  • The Age Pathway
  • The Polyol Pathway
  • The Hexosamine Pathway
  • Protein Kinase C (PKC) Pathway and poly (ADP-ribose) Polymerase (PARP)
  • Neurotrophic Factors and Nerve Repair
  • Treatment of Diabetic Neuropathies
  • Disease State Modifiers
  • Pain-controlling Agents
  • Medications for Neuropathic Pain
  • Treatment of Autonomic Neuropathy
  • Conclusions
  • References
  • Chapter 52: Neurologic Disorders Associated With Disease of the Ovaries and testis
  • Introduction
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging Investigations
  • Pathology
  • Management
  • Infertility, Infecundity, Androgen Receptor Insensitivity Syndrome, and Primary Ovarian Failure in Patients with Neurologi ...
  • Common, non-neurologic Causes of Infertility in Males and Females
  • Fragile X Syndrome
  • Introduction
  • History
  • Clinical Findings
  • Natural History
  • Pathology
  • Laboratory Investigations
  • Management
  • Kennedy's Disease
  • Introduction
  • History
  • Natural History
  • Pathology
  • Laboratory Investigations
  • Management
  • Myotonic Dystrophy
  • Introduction
  • History
  • Natural History
  • Laboratory Investigations
  • Treatment
  • Miscellaneous
  • References
  • Chapter 53: Neurologic Complications of Multiple Endocrine Syndromes
  • Introduction
  • Autoimmune Polyglandular Syndrome Type I
  • Introduction
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging
  • Pathology
  • Management
  • Autoimmune Polyglandular Syndrome Type II
  • Introduction
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging and Pathology
  • Management
  • Autoimmune Polyglandular Syndrome Type III
  • Introduction
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging and Pathology
  • Management
  • Multiple Endocrine Neoplasia
  • Introduction
  • Multiple Endocrine Neoplasia: Men Type 1
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging
  • Neuropathology
  • Management
  • Multiple Endocrine Neoplasia: Men Type 2A
  • History
  • Natural History
  • Laboratory Investigations
  • Neuroimaging
  • Management
  • Multiple Endocrine Neoplasia: Men Type 2B
  • History
  • Natural History
  • Laboratory Investigations
  • Neuroimaging
  • Neuropathology
  • Management
  • References
  • Chapter 54: Commonly Used Endocrine Drugs
  • Introduction
  • Hypothalamic and Pituitary Hormones and Analogs
  • Hypothalamic Hormones and Analogs
  • Somatostatin and Somatostatin Analogs
  • Dopamine and Dopamine Agonists
  • Anterior Pituitary Lobe Hormones And analogs
  • Somatropin (growth Hormone) and Somatropin Agonists
  • Somatropin (growth Hormone) Antagonists
  • Posterior Pituitary Hormones
  • Vasopressin and Analogs
  • Vasopressin Antagonists
  • Thyroid and Parathyroid Agents
  • Thyroid Hormones
  • Antithyroid Preparations
  • Thionamides
  • Perchlorates
  • Parathyroid Hormones and Analogs
  • Drugs Used in Diabetes
  • Insulins and Analogs
  • Short- and rapid-acting Insulins
  • Intermediate and long-acting Insulins
  • Noninsulin Blood glucose-lowering Drugs
  • Biguanides
  • Sulfonamides, Urea Derivatives
  • a-Glucosidase Inhibitors
  • Thiazolidinediones
  • Dipeptidyl Peptidase 4 (DPP-4) Inhibitors
  • Meglitinides
  • Glucagon-like peptide-1 (GLP-1) Receptor Analog (incretin Mimetics)
  • Amylin Analog
  • Aldose Reductase Inhibitors
  • References
  • Section 7: Neurologic Aspects of Metabolic Diseases
  • Chapter 55: Disorders of Purines and Pyrimidines
  • Overview
  • Disorders of Purine Metabolism
  • Gout
  • Phosphoribosylpyrophosphate Synthetase
  • Hypoxanthine-guanine Phosphoribosyltransferase Deficiency
  • Adenylsuccinate Lyase Deficiency
  • 5-Amino-4-imidazolecarboxamide Ribotide transformylase/IMP Cyclohydrolase deficiency
  • 5'-Nucleotidase
  • Purine Nucleoside Phosphorylase Deficiency
  • Adenine Deaminase Deficiency
  • Deoxyguanosine Kinase Deficiency
  • Xanthine Oxidase Deficiency (hereditary xanthinuria)
  • Molybdenum Cofactor Deficiency
  • Myoadenylate Deaminase Deficiency
  • Glucose-6-phosphatase Deficiency
  • Disorders of Pyrimidine Metabolism
  • Orotic Aciduria
  • Pyrimidine Nucleotide Depletion and Overactive Cytosolic 5'-nucleotidase
  • Dihydropyrimidine Dehydrogenase Deficiency
  • Dihydropyrimidinase Deficiency (dihyropyrimidinuria)
  • Ureidopropionase Deficiency
  • Less well-defined Pyrimidine Catabolic disorders
  • Summary
  • References
  • Chapter 56: Porphyria and Its Neurologic Manifestations
  • Introduction
  • Background
  • Clinical Presentation
  • Risk Factors for Attacks
  • Mechanisms of Nervous System dysfunction
  • Diagnosis
  • Treatment
  • Conclusions
  • References
  • Chapter 57: Disorders of Heavy Metals
  • Introduction
  • Copper Disorders
  • Copper Metabolism
  • ATP7A- or ATP7B-related Inherited Copper transport Disorders
  • ATP7A-related Copper Transport Disorders
  • ATP7B-related Copper Transport Disorders
  • Physiopathology
  • Clinical Features
  • Wilson Disease Diagnosis
  • Wilson Disease Treatment
  • Acquired Diseases Associated with Copper Deficiency or Copper Excess
  • Acquired Copper Deficiency
  • Acquired Copper Toxicosis
  • Iron Disorders
  • Iron Metabolism
  • Disorders
  • Inherited Neurodegeneration with brain Iron accumulation
  • Nbia Type 1: Pantothenate kinase-associated Neurodegeneration
  • Nbia Type 2: Classic Infantile Neuroaxonal Dystrophy and Atypical Neuroaxonal Dystrophy
  • Idiopathic Neurodegeneration With Brain Iron Accumulation
  • Neuroferritinopathy
  • Aceruloplasminemia
  • Genetic Systemic Iron Accumulation With Neurologic Features
  • Acquired Neurodegenerative Disorders Such as Alzheimer Disease and Parkinson Disease
  • Acquired Diseases Associated With Iron Excess Or iron Deficiency
  • Restless Legs Syndrome
  • References
  • Chapter 58: Disorders of Bone and Bone Mineral Metabolism
  • Calcium and Parathyroid Hormone Disorders
  • Introduction
  • Hypercalcemia
  • Classification
  • Clinical Features
  • Treatment
  • Primary Hyperparathyroidism
  • Introduction
  • Etiology
  • Diagnosis
  • Clinical Features
  • Skeletal Manifestations
  • Renal Manifestations
  • Cardiovascular Manifestations
  • Gastrointestinal Manifestations
  • Neuromuscular and Neuropsychiatric Manifestations
  • Management
  • Hypocalcemia
  • Classification
  • Clinical Features
  • Treatment
  • Hypoparathyroidism and Pseudohypoparathyroidism
  • Clinical Manifestations
  • Treatment
  • Magnesium and Phosphorus Disorders
  • Magnesium
  • Classification of Hypomagnesemia
  • Clinical Manifestations of Hypomagnesemia
  • Treatment
  • Hypermagnesemia
  • Clinical Manifestations
  • Treatment
  • Congenital and Acquired Phosphorus Disorders
  • Hypophosphatemia
  • Classification
  • Clinical Manifestations
  • Treatment
  • Hyperphosphatemia
  • Classification
  • Clinical Manifestations
  • Treatment
  • Osteoporosis
  • Introduction
  • Etiology
  • Clinical Manifestations
  • Treatment
  • Paget's Disease
  • Introduction
  • Clinical Manifestations
  • Diagnosis
  • Treatment
  • Hypophosphatasia
  • Introduction
  • Clinical Manifestatations
  • Diagnosis
  • Treatment
  • Vitamin D and Central Nervous system From Fetal Life to aging, and From Good Health to Illness
  • Production and Presence of Vitamin D and Its Receptor in the Central Nervous System
  • Vitamin D and Neurogenesis
  • Vitamin D and Disorders of the Nervous system
  • Vitamin D, Neurocognition, and Premature Aging
  • Vitamin D and Parkinson Disease
  • Vitamin D and Depression
  • Vitamin D and Multiple Sclerosis
  • Vitamin D and Epilepsy
  • References
  • Section 8: Neurologic Aspects of Nutritional Disorders
  • Chapter 59: Hydrosoluble Vitamins
  • History
  • Thiamin (vitamin B1)
  • Biochemical Function
  • Natural Sources
  • Clinical Findings
  • Nutritional Polyneuropathy
  • Wernicke-Korsakoff Syndrome
  • Cortical Cerebellar Degeneration
  • Thiamin Toxicity
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Riboflavin (vitamin B2)
  • Biochemical Function
  • Natural Sources
  • Genetics
  • Clinical Findings
  • Toxicity
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Niacin Or Nicotinic Acid (Vitamin B3)
  • Biochemical Function
  • Natural Sources and History
  • Clinical Findings
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Pantothenic Acid (vitamin B5)
  • Biochemical Function
  • Natural Sources
  • Clinical Findings
  • Laboratory Investigations
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Pyridoxine Or Pyridoxal (vitamin B6)
  • Biochemical Function
  • Natural Sources
  • Clinical Findings
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Ascorbic Acid (vitamin C)
  • Biochemical Function
  • Clinical Findings
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Sources, Daily Requirements, and Toxic Dosages
  • Conclusions (including Future directions)
  • References
  • Chapter 60: Neurologic Aspects of Cobalamin (B12) Deficiency
  • Introduction
  • Cobalamin
  • Terminology
  • Requirement for and Sources Of cobalamin
  • Functions and Kinetics
  • Causes of Cobalamin Deficiency
  • Clinical Manifestations of Cobalamin Deficiency
  • Investigations
  • Pathology
  • Management
  • References
  • Chapter 61: The Neurology of Folic Acid Deficiency
  • Historical Background
  • Folate Metabolism
  • The Neurology of folate-deficient Megaloblastic Anemia
  • Neuropsychiatric Disorders Without Anemia Or Macrocytosis
  • Folate, Homocysteine, Depression, Dementia, and Aging
  • Folic Acid and Epilepsy
  • Treatment Issues
  • Depression
  • Cognitive Function
  • Neural Tube Defects and Their Prevention
  • Disorders of Folate Metabolism in Infancy and Childhood
  • Clinical Dissociation
  • Metabolic Mechanisms
  • Conclusions
  • Summary
  • References
  • Section 9: Neurologic Aspects of Environmental disorders
  • Chapter 62: Disorders of Body Temperature
  • Introduction
  • Mechanisms of Heat Exchange
  • Basic Pathogenesis of Hyperthermia
  • Basic Pathogenesis of Hypothermia
  • Heat-related Illness
  • Clinical Features
  • Laboratory Studies
  • Management
  • Drug-induced Hyperthermia
  • Clinical Features
  • Laboratory Studies
  • Management
  • Fever in Neurologic Practice
  • Clinical Features
  • Laboratory Findings
  • Management
  • Accidental Hypothermia
  • Clinical Features
  • Laboratory Studies
  • Management
  • Therapeutic Body Temperature Manipulation: Current Technology
  • External Methods
  • Internal Methods
  • Therapeutic Hypothermia
  • Conclusions
  • References
  • Chapter 63: Neurology and Diving
  • Decompression Sickness
  • Arterial Gas Embolism
  • Epidemiology
  • Clinical Manifestations And diagnosis
  • Prevention
  • Diagnosis
  • Treatment
  • First Aid
  • Recompression
  • Adjunctive Therapy
  • Long-term Neurologic Consequences
  • Appendix: Case Examples
  • Decompression Sickness (1)
  • Decompression Sickness (2)
  • Arterial Gas Embolism
  • References
  • Chapter 64: Neurologic Complications of Carbon Monoxide Intoxication
  • Introduction
  • Pathophysiology
  • Pathology
  • Clinical Findings
  • Acute Intoxication
  • Chronic Intoxication
  • Delayed Neuropsychiatric Syndrome
  • Diagnosis
  • Laboratory Tests
  • Neuroimaging Studies
  • Differential Diagnosis
  • Treatment
  • Prognosis
  • References
  • Chapter 65: Lightning and Thermal Injuries
  • History (including Terminology)
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Electrocardiographic Monitoring Of cardiac complications
  • Myoglobinuria
  • Neuroimaging Investigations
  • Pathology
  • Management
  • Fluid Resuscitation
  • Myoglobinuria Clearance
  • Associated Trauma
  • Early Excision and Wound Care
  • Rehabilitation
  • Conclusions (including Future directions)
  • References
  • Chapter 66: Venomous Snake Bites, Scorpions, and Spiders
  • Introduction
  • Historical Background
  • Venom Apparatus
  • Venom
  • Pathophysiology of Envenoming
  • Effects of Venom on the Nervous System
  • Neurotoxins
  • Postsynaptic Toxins (a-toxins and ?-toxins)
  • Presynaptic Toxins (beta-toxin)
  • Presynaptic Facilitating Toxins and Fasciculins
  • Snake Envenoming
  • Epidemiology
  • Elapidae
  • Cobras
  • Kraits
  • Mambas
  • Coral Snakes
  • Australian Elapids
  • Sea Snakes
  • Viperidae
  • Russells Viper (Daboia Russelii)
  • Rattlesnakes (Crotalus)
  • Scorpions
  • Clinical Manifestations
  • Management of Scorpion Envenoming
  • Spiders
  • Clinical Effects of Spider Bites
  • Treatment of Spider Bite
  • Ant, Bee, Hornet, and Wasp (insecta, Hymenoptera) Stings
  • Clinical Manifestations and Treatments
  • Tick Paralysis
  • Other Natural Toxins
  • Management of Snake Bite
  • Immediate Management
  • Treatment in the Hospital
  • Supportive Treatment in Neurotoxic Envenoming
  • Conclusion
  • Acknowledgments
  • References
  • Section 10: Neurologic Aspects of Hematologic Disorders
  • Chapter 67: Anemias Excluding Cobalamin and Folate Deficiencies
  • Introduction
  • Definition and Pathophysiology of Anemias
  • Diagnostic Approach
  • Clinical (including Neurologic) Consequences of Anemia
  • Iron Deficiency Anemia
  • Causes of Iron Deficiency
  • Clinical Findings
  • Laboratory Findings
  • Treatment
  • Anemia of Chronic Inflammation/disease
  • Megaloblastic Anemias Excluding folate and Cobalamin deficiencies
  • Myelodysplastic Syndromes
  • Bone Marrow Failure Syndromes
  • Background
  • Pure Red Cell Aplasia
  • Aplastic Anemia
  • Fanconi's Anemia
  • Anemia Associated With Lead Poisoning
  • Hemolytic Anemias
  • Background
  • Diagnosis and Clinical Findings
  • Treatment
  • Autoimmune Hemolytic Anemia
  • G6PD Deficiency
  • Hereditary Spherocytosis
  • Paroxysmal Nocturnal Hemoglobinuria
  • Hemoglobinopathies
  • Conclusions
  • References
  • Chapter 68: Neurologic Complications of Sickle Cell Disease
  • History
  • Clinical Findings
  • Natural History
  • Laboratory Investigations
  • Neuroimaging
  • Genetics
  • Pathology
  • Management
  • Conclusions
  • References
  • Chapter 69: Neurologic Aspects of Lymphoma and Leukemias
  • Introduction
  • Lymphomas
  • Non-Hodgkins Lymphomas
  • Primary Central Nervous System Lymphoma
  • Burkitt Lymphoma
  • Multiple Myeloma, Plasmacytoma, And amyloidosis
  • Hodgkin Lymphoma
  • Clinical Presentations of Lymphomas
  • Central Nervous System
  • Spinal Cord
  • Leptomeningeal
  • Peripheral Nervous System
  • Infectious Disease
  • Vascular/hematologic
  • Paraneoplastic
  • Leukemias
  • Clinical Presentations of Leukemias
  • Leptomeningeal
  • Central Nervous System
  • Spinal Cord
  • Vascular/hematologic
  • Peripheral Nervous System
  • Conclusion
  • References
  • Chapter 70: Bleeding Diathesis and Hemophilias
  • Introduction
  • Pathophysiology of Hemostasis
  • Hemophilia
  • Epidemiology of Hemophilia
  • Genetics of Hemophilia
  • Clinical Classification of Hemophilia
  • Clinical Manifestations of Hemophilia
  • Frequency of Bleeding
  • Bleeding Symptoms
  • Diagnosis of Hemophilia
  • Coagulation Tests
  • Genetic Testing for Hemophilia
  • Management of Hemophilia
  • Inhibitors of Coagulation Factor VIII And factor IX
  • Acquired Hemophilia
  • Neurologic Manifestations in Patients with Hemophilia
  • Central Nervous System Manifestations
  • Peripheral Nervous System Manifestations
  • Compartment Syndrome
  • Pseudotumors
  • Neurologic Comorbidites Due to Aging
  • Rare Bleeding Disorders
  • Bleeding Symptoms
  • Diagnosis of Rare Bleeding Disorders
  • Scope of Genetic Testing for the Diagnosis of Rare Bleeding Disorders
  • Management of Rare Bleeding Disorders
  • Role of Prophylaxis Therapy in Patients Rare bleeding Disorders
  • Deficiencies of Fibrinolytic Pathway: a2-antiplasmin and Plasminogen Activator inhibitor-1 (PAI-1) Deficiency
  • Von Willebrand Disease
  • Types of Von Willebrand Disease
  • Clinical Presentation
  • Diagnosis of Von Willebrand Disease
  • Treatment of Von Willebrand Disease
  • Platelet Function Disorders
  • Overview of Anatomy and Physiology Of platelets
  • Bleeding Symptoms
  • Diagnosis of Platelet Function Disorders
  • Treatment of Platelet Function Disorders
  • Role of Hemophilia Treatment Centers in the Management of Bleeding Disorders
  • Summary
  • References
  • Chapter 71: Thrombophilic States
  • Thrombophilic States
  • Definition
  • Inherited Thrombophilia
  • Acquired Thrombophilia
  • Mixed Thrombophilia
  • Lipoprotein(a)
  • Thrombophilic States and Cerebral Venous Sinus Thrombosis
  • Epidemiology and Clinical Symptoms
  • Inherited Thrombophilia
  • Acquired Thrombophilia
  • Mixed Thrombophilia
  • Cerebral Venous Sinus Thrombosis in Children
  • Thrombophilic States and Ischemic Stroke
  • Inherited Thrombophilia
  • Acquired Thrombophilia
  • Mixed Thrombophilia
  • Stroke in Children
  • Stroke Related to Paradoxical Embolism
  • Conclusions
  • References
  • Chapter 72: Chronic Myeloproliferative Diseases
  • Introduction and Definitions
  • The JAK2 Mutation and the Relationship Between Polycythemia Vera, Primary Myelofibrosis, and Essential Thrombocythemia
  • Polycythemia Vera
  • Main Clinical Characteristics
  • Diagnostic Criteria and Risk Assessment
  • Frequent Neurologic Symptoms
  • Thrombosis and Hemorrhage
  • Other Neurologic Symptoms
  • General Treatment Recommendations
  • Essential Thrombocythemia
  • Main Clinical Characteristics
  • Diagnostic Criteria and Risk Assessment
  • Neurologic Manifestations
  • General Treatment Recommendations
  • Primary Myelofibrosis
  • Main Clinical Characteristics
  • Diagnostic Criteria and Risk Assessment
  • Neurologic Manifestations
  • General Treatment Recommendations
  • References
  • Chapter 73: Neurologic Aspects of Plasma Cell Disorders
  • Introduction
  • Monoclonal Gammopathy of Undetermined Significance
  • MGUS and Peripheral Neuropathy
  • IGM-related Peripheral Neuropathy, anti-MAG positive
  • IGM-related Peripheral Neuropathy, anti-MAG Negative And/or No Detectable Autoantibody
  • IgG- and IgA-related Neuropathy
  • MGUS and the Central Nervous System
  • Smoldering Multiple Myeloma
  • Multiple Myeloma
  • Multiple Myeloma and Peripheral Neuropathy
  • Multiple Myeloma and treatment-related Neuropathy
  • Multiple Myeloma and the Central Nervous system
  • Epidural Disease in Multiple Myeloma
  • Leptomeningeal Involvement
  • Intracranial Plasmacytoma
  • Metabolic Disturbances
  • Nonsecretory Myeloma
  • Solitary Plasmacytoma
  • Poems Syndrome
  • Poems Syndrome and Peripheral Neuropathy
  • Waldenstrm Macroglobulinemia
  • Waldenström Macroglobulinemia and Peripheral Neuropathy
  • Waldenström Macroglobulinemia and the Central Nervous System
  • Hyperviscosity Syndrome
  • Bing-Neel Syndrome
  • Al Amyloidosis (immunoglobulin Light Chain Amyloidosis)
  • Al Amyloidosis and Peripheral Neuropathy
  • Al Amyloidosis and the Central Nervous system
  • Cryoglobulinemia
  • Cryoglobulinemia and Peripheral Neuropathy
  • Conclusion
  • References
  • Chapter 74: Neurologic Manifestations of Henoch-Schönlein Purpura
  • General Aspects
  • Historical Aspects
  • Systemic Disease
  • Diagnostic Criteria
  • Pathology
  • Etiology and Pathogenesis
  • Epidemiology of Nervous System Manifestations
  • Nervous System Manifestations
  • Cerebrovascular Disease
  • Hypertensive Encephalopathy and Posterior Reversible Encephalopathy Syndrome
  • Disorders of Hemostasis
  • Metabolic Abnormalities and Infections
  • Headache and Mental Status Alterations
  • Seizures
  • Neuro-ophthalmologic Manifestations
  • Myelopathy
  • Neuromuscular Manifestations
  • Investigations
  • Nonspecific Laboratory Findings
  • Antineutrophil Cytoplasmic Antibodies
  • Cerebrospinal Fluid Analysis
  • Imaging Studies
  • Differential Diagnosis
  • Management
  • Prognosis
  • References
  • Chapter 75: Hemolytic Uremic Syndrome
  • Introduction
  • Definition
  • Epidemiology and Etiology
  • Typical Hemolytic Uremic Syndrome
  • Atypical Hemolytic Uremic Syndrome
  • Thrombotic Thrombocytopenic Purpura
  • Pathophysiology
  • Typical Hemolytic Uremic Syndrome
  • Atypical Hemolytic Uremic Syndrome
  • Clinical Manifestations
  • Neurologic Findings and Sequelae
  • Diagnosis
  • Treatment
  • Antibiotics
  • Cobalamin Replacement
  • Plasma Infusion and Plasmapheresis
  • Immunotherapy
  • Transplantation
  • Complement Therapy
  • Commonly Used Drugs in Hematologic Disorders
  • Agents Used to Treat Benign Hematologic Disorders
  • Replacement Therapies
  • Anemias Resulting From Iron And vitamin deficiencies
  • Coagulopathies
  • Fresh Frozen Plasma
  • Cryoprecipitate
  • Immunoglobulin
  • Transfusion Reactions and Risks
  • Recombinant Factor VIIa
  • Prothrombin Complex Concentrates
  • Antifibrinolytic Agents
  • Lysine Analogs
  • Antiplatelet Agents
  • Cyclooxygenase Inhibitors
  • Adenosine Diphosphate Receptor Inhibitors
  • Glycoprotein IIb/IIIa Antagonists
  • Thromboxane Synthase Inhibitors
  • Antithrombotic Agents
  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Factor Xa Inhibitors
  • Warfarin
  • Direct Thrombin Inhibitors
  • Management of Hemorrhagic Complications of Anticoagulation
  • Intracranial Hemorrhages
  • Warfarin
  • Unfractionated and Low Molecular Weight heparin
  • Direct Thrombin Inhibitors
  • Antiplatelet Agents
  • Agents Used to Treat Hematologic malignancies
  • Chronic Myeloproliferative Neoplasms
  • Hydroxyurea
  • Anagrelide
  • BCR-ABL Tyrosine Kinase Inhibitors
  • Myelodysplasia
  • DNA Methyltransferase Inhibitors And nucleoside Analogs
  • Leukemias, Lymphomas, and Multiple myeloma
  • Chemotherapeutic Agents
  • Targeted Therapies
  • Monoclonal Antibodies
  • Radioimmunotherapy
  • Immunomodulatory Drugs
  • Proteosome Inhibitors
  • References
  • Index

Contributors


R.J. Adams,     South Carolina Stroke Center of Economic Excellence and Medical University of South Carolina Stroke Center, Charleston, SC, USA

C.L. Ahrens,     Neurological Intensive Care Unit, Cleveland Clinic Cleveland, OH, USA

A. Aggarwal,     Center for Brain and Nervous System, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

L. Agrawal,     Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, IL, USA

C. Amin,     Indiana Hemophilia and Thrombosis Centre, Indianapolis, IN, USA

E. Anderes,     Division of Hematology and Oncology, Department of Medicine, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

H.C. Andersson,     Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA, USA

N. Azad,     Edward Hines Jr. VA Hospital, Hines, IL, USA

J.R. Berger,     Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA

M.D. Bérubé,     Department of Neurology, Centre Hospitalier de l’Université de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, QC, Canada

T.E. Bertorini,     Department of of Neurology, Methodist University Hospital and Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA

K. Betterman,     Department of Neurology, Penn State College of Medicine, Hershey, PA, USA

M. Bhatt,     Center for Brain and Nervous System, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

N. Blais,     Department of Haematology, Centre Hospitalier de l’Université de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, QC, Canada

P. Bucciarelli,     A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

P. Camacho,     Loyola University Osteoporosis and Metabolic Bone Disease Center, Loyola University Medical Center, Maywood, IL, USA

G. Charnogursky,     Division of Endocrinology and Metabolism, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

J. Chawla,     Department of Neurology, Hines VA Hospital, Hines and Department of Neurology, Loyola University Medical Center, Maywood, IL, USA

L. Correia,     Department of Gastroenterology and Hepatology, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal

S. Datar,     Division of Critical Care Neurology, Mayo Clinic, Rochester, MN, USA

J.F. de Lacerda,     Department of Hematology and Bone Marrow Transplantation, Hospital de Santa Maria, Lisbon, Portugal

T. Dias,     Endocrinology, Diabetes and Metabolism Unit, Hospital de Santa Maria, Lisbon, Portugal

S. Dublis,     Division of Hematology and Oncology, Department of Medicine, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

A.P. Duker,     Department of Neurology, University of Cincinnati, Cincinnati, OH, USA

P.J.B. Dyck,     Mayo Clinic, Department of Neurology, Rochester, MN, USA

M.A. Emanuele,     Division of Endocrinology and Metabolism, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

N.V. Emanuele,     Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, and Endocrinology Section, Edward Hines Jr. VA Hospital, Hines, IL, USA

J.M. Ferro,     Neurology Service, Department of Neurosciences, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal

P. Foy,     Department of Hematology, Medical College of Wisconsin, Milwaukee, WI, USA

R.L. Gamelli,     Department of Surgery, Loyola University Medical Center, Maywood, IL, USA

C.R. Gomez,     Neurological Institute of Alabama, Birmingham, AL, USA

A. Griest,     Indiana Hemophilia and Thrombosis Centre and Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

G. Gruener,     Department of Neurology and Leischner Institute for Medical Education, Loyola University Medical Center, Maywood, IL, USA

Z. Habib,     Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, IL, USA

M. Hadjivassiliou,     Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK

J.C. Kattah,     Department of Neurology, University of Illinois College of Medicine, Peoria, IL, USA

W.C. Kattah,     Endocrinology Department, University of the Andes, Bogota, Colombia

R.E. Kelley,     Department of Neurology, Tulane University School of Medicine, New Orleans, LA, USA

M. Komoroski,     Loyola University Osteoporosis and Metabolic Bone Disease Center, Loyola University Medical Center, Maywood, IL, USA

S.A.M. Kularatne,     Department of Medicine, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka

N. Kumar,     Department of Neurology, Mayo Clinic, Rochester, MN, USA

D. Kvarnberg,     Department of Neurology, Loyola University Medical Center, Maywood, IL, USA

S. Lanthier,     Department of Neurology, Centre Hospitalier de l’Université de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, QC, Canada

H. Lee,     Division of Endocrinology and Metabolism, Loyola University Stritch School of Medicine, Maywood, IL, USA

N. Lopez,     Division of Endocrinology and Metabolism, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

I. Martinelli,     A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

E.W. Massey,     Department of Neurology, Duke University Medical Center, Durham, NC, USA

A. Mazhari,     Division of Endocrinology and Metabolism, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

E.M. Manno,     Neurological Intensive Care Unit, Cleveland Clinic, Cleveland, OH, USA

M. McCoyd,     Department of Neurology, Loyola University Medical Center, Maywood, IL, USA

R.E. Moon,     Departments of Anesthesiology and Medicine, Duke University Medical Center, Durham, NC, USA

S....

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

202,30 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung des WebShops erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok